Cargando…

Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma

Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Takashi, Takata, Kazuhide, Yokoyama, Keiji, Fukuda, Hiromi, Yamauchi, Ryo, Fukunaga, Atsushi, Shakado, Satoshi, Sakisaka, Shotaro, Hirai, Fumihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324802/
https://www.ncbi.nlm.nih.gov/pubmed/35877241
http://dx.doi.org/10.3390/curroncol29070381
_version_ 1784756888375656448
author Tanaka, Takashi
Takata, Kazuhide
Yokoyama, Keiji
Fukuda, Hiromi
Yamauchi, Ryo
Fukunaga, Atsushi
Shakado, Satoshi
Sakisaka, Shotaro
Hirai, Fumihito
author_facet Tanaka, Takashi
Takata, Kazuhide
Yokoyama, Keiji
Fukuda, Hiromi
Yamauchi, Ryo
Fukunaga, Atsushi
Shakado, Satoshi
Sakisaka, Shotaro
Hirai, Fumihito
author_sort Tanaka, Takashi
collection PubMed
description Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment for u-HCC in a real-world setting. Methods: This retrospective study was conducted between January 2021 and April 2022. Twenty-eight patients with u-HCC, who were treated with ATZ + BV, were assessed for their treatment response, continuation, and adverse events (AEs). Results: Among the 28 patients, 24 were evaluated at the first imaging. The objective response rate (ORR) was 29.2% (n = 7), and 54.2% (n = 13) on the response evaluation criteria in solid tumors (RECIST 1.1) and in the modified RECIST (mRECIST) guidelines, respectively. Comparing the objective response (OR) group (n = 13) and the non-OR group (n = 11), the modified albumin–bilirubin (mALBI) grades 1 and 2a were found to be significant predictive factors for OR (p = 0.021) in the mRECIST guidelines. Among the 28 patients, 17 discontinued their treatment due to AEs. Comparing the treatment continuation (n = 11) and discontinuation groups (n = 17), a Child–Pugh score of five points (p = 0.009) and mALBI grades 1 and 2a (p = 0.020) were predictive factors with significant differences. Conclusions: Pretreatment mALBI grades 1 and 2a were the important predictive factors associated with the therapeutic response and the therapeutic continuation of ATZ + BV for patients with u-HCC.
format Online
Article
Text
id pubmed-9324802
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93248022022-07-27 Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma Tanaka, Takashi Takata, Kazuhide Yokoyama, Keiji Fukuda, Hiromi Yamauchi, Ryo Fukunaga, Atsushi Shakado, Satoshi Sakisaka, Shotaro Hirai, Fumihito Curr Oncol Communication Background: Atezolizumab plus bevacizumab (ATZ + BV) treatment is recommended as the first-line systemic therapy for patients with unresectable hepatocellular carcinoma (u-HCC). This study aimed to investigate the predictive factors of therapeutic response and the continuation of ATZ + BV treatment for u-HCC in a real-world setting. Methods: This retrospective study was conducted between January 2021 and April 2022. Twenty-eight patients with u-HCC, who were treated with ATZ + BV, were assessed for their treatment response, continuation, and adverse events (AEs). Results: Among the 28 patients, 24 were evaluated at the first imaging. The objective response rate (ORR) was 29.2% (n = 7), and 54.2% (n = 13) on the response evaluation criteria in solid tumors (RECIST 1.1) and in the modified RECIST (mRECIST) guidelines, respectively. Comparing the objective response (OR) group (n = 13) and the non-OR group (n = 11), the modified albumin–bilirubin (mALBI) grades 1 and 2a were found to be significant predictive factors for OR (p = 0.021) in the mRECIST guidelines. Among the 28 patients, 17 discontinued their treatment due to AEs. Comparing the treatment continuation (n = 11) and discontinuation groups (n = 17), a Child–Pugh score of five points (p = 0.009) and mALBI grades 1 and 2a (p = 0.020) were predictive factors with significant differences. Conclusions: Pretreatment mALBI grades 1 and 2a were the important predictive factors associated with the therapeutic response and the therapeutic continuation of ATZ + BV for patients with u-HCC. MDPI 2022-07-08 /pmc/articles/PMC9324802/ /pubmed/35877241 http://dx.doi.org/10.3390/curroncol29070381 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Tanaka, Takashi
Takata, Kazuhide
Yokoyama, Keiji
Fukuda, Hiromi
Yamauchi, Ryo
Fukunaga, Atsushi
Shakado, Satoshi
Sakisaka, Shotaro
Hirai, Fumihito
Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
title Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
title_full Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
title_fullStr Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
title_full_unstemmed Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
title_short Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
title_sort pretreatment modified albumin–bilirubin grade is an important predictive factor associated with the therapeutic response and the continuation of atezolizumab plus bevacizumab combination therapy for patients with unresectable hepatocellular carcinoma
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324802/
https://www.ncbi.nlm.nih.gov/pubmed/35877241
http://dx.doi.org/10.3390/curroncol29070381
work_keys_str_mv AT tanakatakashi pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma
AT takatakazuhide pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma
AT yokoyamakeiji pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma
AT fukudahiromi pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma
AT yamauchiryo pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma
AT fukunagaatsushi pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma
AT shakadosatoshi pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma
AT sakisakashotaro pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma
AT hiraifumihito pretreatmentmodifiedalbuminbilirubingradeisanimportantpredictivefactorassociatedwiththetherapeuticresponseandthecontinuationofatezolizumabplusbevacizumabcombinationtherapyforpatientswithunresectablehepatocellularcarcinoma